Injectable Hydrogel Compositions for Brain Tumor Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for brain cancers, such as glioblastoma, are limited by their inability to reach all tumor cells, lack of specificity, and the development of drug resistance, leading to poor patient outcomes.
Innovation Solution
The development of hydrogel compositions that can be injected or sprayed onto brain tumors, providing controlled and sustained release of chemotherapy and immunotherapy drugs, including doxorubicin and cyclic dinucleotides, to enhance drug delivery and reduce resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapy and radiation therapy are used to eliminate residual tumor cells, then tumor cell elimination is improved, but the therapy cannot reach all tumor cells and tumor cells develop resistance
Solution Approach 1:
The patent uses wafers as intermediary carriers to deliver chemotherapy drugs directly to the tumor site. These wafers are placed in the resection cavity and release drugs locally, serving as a mediator between the treatment system and the residual tumor cells, enabling targeted delivery that overcomes the limitations of systemic chemotherapy and radiation.
Solution Approach 2:
The invention implements local quality by concentrating high doses of chemotherapy drugs specifically at the tumor resection site through wafer placement. This localized high-concentration delivery ensures that all residual tumor cells in the cavity are exposed to effective drug levels, addressing the inability of systemic therapies to reach all tumor cells uniformly.
2Reliability
If GLIADEL wafer is used for therapeutic delivery to brain tumors, then direct therapeutic delivery is improved, but wafer migration and mechanical mismatch with soft tissue occur
Solution Approach 1:
The patent modifies the physical and chemical parameters of the wafer material to match the mechanical properties of brain tissue. By adjusting factors such as elasticity, viscosity, and compositional makeup, the wafer achieves mechanical compatibility with the soft brain tissue, preventing migration and improving positional stability while maintaining therapeutic delivery effectiveness.
3Reliability
If GLIADEL wafer is used for drug delivery, then therapeutic delivery is improved, but rapid drug release and slow material degradation occur
Solution Approach 1:
The invention implements dynamic drug release by designing the wafer material to progressively change its drug release rate over time. The system transitions from rapid initial release to sustained slower release, matching the therapeutic needs at different stages of tumor treatment. This dynamic behavior allows the wafer to provide high initial concentrations followed by prolonged maintenance dosing.
Solution Approach 2:
The patent employs periodic or staged drug release patterns where the wafer delivers drugs in controlled phases. This periodic action allows for initial high-dose delivery followed by sustained lower-dose release, creating a temporal pattern that maximizes therapeutic effectiveness while managing side effects and addressing the timing of tumor cell vulnerability.
4Reliability
If potent chemotherapies are used to treat brain tumors, then tumor cell killing is improved, but drug toxicity increases
Solution Approach 1:
The invention applies local quality by delivering potent chemotherapeutic agents concentrated specifically at the tumor resection site through the wafer system. This localized delivery ensures that high doses of toxic drugs are confined to the target area, maximizing tumor cell killing while minimizing exposure and toxicity to surrounding healthy brain tissue and the patient's body.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel compositions offer improved drug diffusion, stability at the resection site, and multiple mechanisms of action, including immunogenic cell death, potentially extending patient survival and reducing scar formation.
Implementation Method 1
achieve increased drug diffusion from resection cavities to disseminate tumor foci
Data Source
AI summary
Compositions for local delivery of a drug to an intracranial region, such as brain tissue or a brain tumor. Methods for locally delivering drug or therapy to an intracranial region. Compositions may include a hydrogel in which a chemotherapy drug or immunotherapy drug is dispersed. Kits that include compositions or solutions that may be combined to form compositions.